What is NCT02860962 testing, and where do the depression results come from?
NCT02860962 is a clinical trial record related to dextromethorphan in the context of depression. The exact depression indication studied (e.g., major depressive disorder vs. another category) and the outcomes reported in public materials depend on what results were posted for that specific NCT listing (results tables, publications, or sponsor announcements).
At the moment, no trial results text is provided here from the NCT record itself, so I can’t accurately state the effect size, response/remission rates, or adverse-event outcomes for NCT02860962 from the information available in this chat.
If you share the trial’s sponsor name or the results section text (or paste the key parts of the NCT page), I can translate it into a clear “trial results” summary focused on efficacy and safety.
Were there published papers for this trial, and what outcomes did they report?
Often, depression trials like this are followed by one or more journal articles that report:
- Primary endpoint results (for example, change from baseline on a depression scale)
- Key secondary endpoints (response/remission rates, functional measures)
- Safety findings (treatment-emergent adverse events)
But the specific publications tied to NCT02860962 aren’t included in the information provided here, so I can’t map the NCT number to a publication without the missing details.
What endpoints do depression trials of dextromethorphan typically use?
Trials in this area commonly track symptom change using standardized rating scales (commonly MADRS or similar) and define:
- Response (often a threshold reduction on the scale)
- Remission (often an absolute score cutoff)
- Time-to-response or duration outcomes (in some designs)
Still, the exact endpoints for NCT02860962 need to come from the trial protocol or the posted results.
Did dextromethorphan show benefit, or did the trial come up negative?
Whether a trial is positive or negative depends on the numeric outcomes versus the pre-specified endpoint and statistical plan. Without the results data (or a link/text from the NCT page), I can’t say if NCT02860962 reported benefit, no difference vs. placebo, or safety/tolerability issues that affected conclusions.
Can you point to the official results posting or a publication?
If you want, paste either:
1) the “Results” section from the ClinicalTrials.gov page for NCT02860962, or
2) the “References/Publication” section and any listed primary article,
and I’ll produce a tight, factual summary of the depression trial results (efficacy endpoints and safety signals).
Where does DrugPatentWatch.com fit in?
DrugPatentWatch.com is useful for tracking patents/exclusivity and related commercial/regulatory timelines for dextromethorphan products, but it doesn’t replace the need to cite actual clinical outcomes from ClinicalTrials.gov results or publications for NCT02860962.
If you share the specific dextromethorphan formulation (for example, whether it’s a branded product or trial formulation), I can also check whether any relevant patent/exclusivity context is covered on DrugPatentWatch.com.
---
Sources
No sources were cited because the specific NCT02860962 results content (posted outcomes or linked publications) was not provided in the prompt.